Bristol-Myers Squibb Ranks No. 2 Among Fast Company’s Most Innovative Companies in Biotech for 2016

We are honored and proud that Bristol-Myers Squibb is among Fast Company’s Most Innovative Companies for 2016 and that our passion for developing and delivering transformational medicines helped earn us the number two spot in the rankings’ Biotech category this year. 

To be included among companies that we admire and that have revolutionized their industries and blazed their own trails — including Google, Apple and Twitter — is extremely gratifying. But what makes this recognition by Fast Company truly humbling comes back to why we are relentless in our pursuit to innovate at Bristol-Myers Squibb in the first place. 

Simply put, we are here for the patients. 

Each and every day, our colleagues – some 25,000 men and women across the globe — come to work at Bristol-Myers Squibb with a shared commitment and perseverance to carry out our mission to help patients prevail over serious diseases. 

It is remarkable that the future of cancer care is now driven in part by the Immuno-Oncology science that our researchers pioneered years ago, and that it is becoming a reality for many patients at a historically fast pace – dozens of regulatory approvals for I-O agents across the world in 2015 alone. We are a fast company, indeed. 

Even more remarkable, this level of performance goes on every day, in every Bristol-Myers Squibb portfolio, program and office – from manufacturing to marketing, to medical affairs and market access, field representatives to research and development, and all support teams that make these functions possible. Innovation at Bristol-Myers Squibb is not only about products, it is too as well about how we do our work and how we interact with our customers and stakeholders. 

Our foundational commitment to improving the lives of patients runs through our entire organizationand it encompasses not only pioneering research with the potential to change clinical practice, but also empowering patients to be champions of their own healthcare, and supporting community-driven public health campaigns around the world. 

There’s a true sense of urgency to the work we are doing that comes from knowing patients and their loved ones are counting on us. They are the raison d’etre — as we say in French — behind our innovation. 

In our minds, innovation at Bristol-Myers Squibb is not a choice. Innovation is both a business and a moral imperative.